In the 2020 revision of the American College of Cardiology and American Heart Association HF guidelines, angiotensin receptor-neprilysin inhibitors replaced ACE inhibitors and ARBs as the recommended first-line treatment for HF with reduced EF.38 The gene discussed is ACE; the disease is hydrops fetalis.